# Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

> **NCT03895684** · PHASE1 · COMPLETED · sponsor: **Salarius Pharmaceuticals, LLC** · enrollment: 23 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SP-2577 Seclidemstat

## Key facts

- **NCT ID:** NCT03895684
- **Lead sponsor:** Salarius Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-25
- **Primary completion:** 2021-04-13
- **Final completion:** 2021-04-13
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895684, "Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03895684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*